EN | UA
EN | UA

Help Support

Back

Amisulpride injection is now available for postoperative nausea and vomiting

Amisulpride injection is now available for postoperative nausea and vomiting Amisulpride injection is now available for postoperative nausea and vomiting
Amisulpride injection is now available for postoperative nausea and vomiting Amisulpride injection is now available for postoperative nausea and vomiting

What's new?

Individuals suffering from postoperative nausea and vomiting can now benefit from FDA-approved amisulpride injection.

As on 24th August 2020, a commercial-stage biopharmaceutical company announced that its amisulpride (selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist) injection has been launched and is now available in the US for order and distribution to customers via main wholesalers and speciality distributors. 


On 26 February 2020, this injection was FDA-approved for the management of postoperative nausea & vomiting (PONV). PONV is a frequent complication of surgery. It is linked with the usage of anesthetic gases and opioid analgesics, which is especially common following abdominal, gynecological, eye, and ear surgeries, especially those with a duration of an hour or more. This injection is the only antiemetic agent which has been approved as a rescue PONV treatment in patients who have unsuccessful earlier antiemetic prophylaxis of other drug class. 

This injection is expected to be in high demand as US healthcare organizations pursue to address surgical buildups created by the coronavirus crisis, mentioned the company’s CEO.

Article:

BARHEMSYS® (amisulpride injection) Launched in the US for the Treatment and Prevention of PONV

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: